KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Buys 14,562 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were bought at an average cost of $9.22 per share, for a total transaction of $134,261.64. Following the completion of the acquisition, the insider now owns 5,012,796 shares in the company, valued at $46,217,979.12. This represents a 0.29 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Stock Up 3.5 %

KALV stock opened at $9.22 on Tuesday. The firm has a market cap of $455.65 million, a price-to-earnings ratio of -2.53 and a beta of 0.85. The company’s fifty day simple moving average is $8.81 and its 200 day simple moving average is $10.81. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.01. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KALV. SG Americas Securities LLC raised its holdings in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock valued at $123,000 after purchasing an additional 1,319 shares during the last quarter. HighVista Strategies LLC lifted its position in shares of KalVista Pharmaceuticals by 4.5% during the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after buying an additional 1,432 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after acquiring an additional 1,670 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 2,043 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after acquiring an additional 3,314 shares during the period.

Wall Street Analysts Forecast Growth

KALV has been the topic of several research analyst reports. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday. They set an “outperform” rating and a $19.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Bank of America assumed coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective for the company. Finally, TD Cowen began coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).